Lung and Upper Aerodigestive Cancers Research Group
we propose to use targeted massively parallel DNA sequencing to identify somatic alterations within mutational hotspots in matched sets of primary lung tumors, premalignant lesions, and adjacent,histologically normal lung tissue.
1. Use targeted massively parallel DNA sequencing to assess the presence of mutations in specific genomic
regions in matched sets of primary lung adenocarcinomas, premalignant lesions, and adjacent,
histologically normal lung tissues obtained from the same patient.
What is the prevalence of common lung-cancer-associated mutations in a panel of adenocarcinomas or
premalignant lesions from the same patient? What is their baseline prevalence in lung tissue with no histologic
indication of disease?
2. To identify mutations whose prevalence is significantly higher in tumors and premalignant lesions than in
histologically normal lung tissue from the same patient, assess the variability of this prevalence among
independent specimens within each patient, and examine the biological relationship between mutations
whose prevalence is covariant across patients.
Which mutations may be useful as early markers of lung cancer in patients with subclinical disease and which
may be clinically actionable? How much does the spectrum of known cancer-associated mutations vary
between independent premalignant lesions or different samples of the same primary tumor? Are there
mutations that are frequently associated with each other or mutually exclusive, and if so, does this covariance
reflect the biological relationship of the genes in which they occur?
There are currently no biomarkers annotated for this protocol.
No datasets are currently associated with this protocol.
The In-person EDRN Orientation Meeting will take place Wednesday, October 19–Friday, October 21, 2016 in Bethesda, MD. More information such as meeting registration and hotel reservations will be sent to new/continuing EDRN members soon.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.